Telesis Bio Q2 Adj $(7.62) Misses $(4.03) Estimate, Sales $1.55M Miss $6.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Telesis Bio (NASDAQ:TBIO) reported Q2 losses of $(7.62) per share, missing the analyst estimate of $(4.03) by 89.08%. Sales were $1.55M, missing the $6.50M estimate by 76.15%. This represents a significant decline from the same period last year.
August 07, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Telesis Bio reported Q2 losses of $(7.62) per share, significantly missing the analyst estimate of $(4.03). Sales were also disappointing at $1.55M, far below the $6.50M estimate. Both figures represent substantial declines from the same period last year.
The significant miss on both EPS and sales estimates, coupled with substantial year-over-year declines, is likely to negatively impact TBIO's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100